Kala Bio, INC Form 4 insider transactions

Romulus Brazzell, Head of Research and Development and Chief Medical Officer at Kala Bio, reports the acquisition of stock options and restricted stock units, as well as the sale of shares to cover tax obligations.

Kala Bio's CEO, Mark Iwicki, executed stock sales to cover tax obligations and received a new stock option grant, as detailed in a recent SEC Form 4 filing.

Kala Bio's Chief Financial Officer, Mary Reumuth, reported the acquisition of restricted stock units, the sale of common stock, and the grant of stock options.

Baker Bros. Advisors LP and related entities acquired additional shares of KALA BIO, Inc. common stock through a private placement, increasing their beneficial ownership.

Todd Bazemore, President and COO of KALA BIO, Inc., sold 4,653 shares of common stock on June 26, 2024, to cover tax withholding obligations related to vested restricted stock units.

Darius Kharabi, Chief Business Officer of KALA BIO, Inc., sold 5,158 shares of common stock on June 26, 2024, to cover tax withholding obligations related to vested restricted stock units.

Mary Reumuth, CFO of KALA BIO, Inc., sold 4,163 shares of common stock on June 26, 2024, to cover tax withholding obligations related to vested restricted stock units.

KALA BIO CEO Mark Iwicki sold 15,168 shares of common stock on June 26, 2024, at an average price of $4.75 to cover tax withholding obligations related to vested restricted stock units.

Romulus K. Brazzell, Head of Research and Development and Chief Medical Officer at KALA Bio, Inc., sold 5,489 shares of common stock on June 26, 2024, to cover tax withholding obligations related to vested restricted stock units.

Director Howard B Rosen reports acquisition of 1,400 shares of common stock and options to purchase 3,150 shares of common stock in KALA BIO, Inc.

Director Farid Marjan reports acquisition of restricted stock units and stock options in KALA BIO, Inc.

Director Gregory D. Perry reported the acquisition of common stock and stock options in KALA BIO, Inc. through a grant of restricted stock units and a stock option award.

Director C. Daniel Myers reported the acquisition of common stock and stock options in KALA BIO, Inc. on June 11, 2024.

Director Andrew Koven reported the acquisition of stock options and restricted stock units in KALA BIO, Inc.

Mark S. Blumenkranz, a director at KALA BIO, Inc., received stock options and restricted stock units, as reported in a recent SEC Form 4 filing.

Todd Bazemore, President and COO of KALA BIO, Inc., sold 2,093 shares of common stock at an average price of $6.09 to cover tax withholding obligations related to vested restricted stock units.

Darius Kharabi, Chief Business Officer of Kala Bio, sold 231 shares of common stock at an average price of $6.09 to cover tax withholding obligations related to vested restricted stock units.

Mary Reumuth, CFO of KALA BIO, Inc., sold 1,786 shares of common stock on May 31, 2024, to cover tax withholding obligations related to vested restricted stock units.

Romulus K. Brazzell, Head of Research and Development and Chief Medical Officer at KALA BIO, Inc., sold 2,002 shares of common stock on May 31, 2024, to cover tax withholding obligations related to vested restricted stock units.

KALA Bio's CEO, Mark Iwicki, sold 7,392 shares of common stock on May 31, 2024, to cover tax withholding obligations related to vested restricted stock units.